Alan Tan, MD, discusses upcoming trials that could change the landscape of frontline and adjuvant renal cell carcinoma ...

Sangamo (SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate ST-920 in the treatment of Fabry disease. Read more here.

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...

The global continuous renal replacement therapy market is set for significant expansion, with projections indicating a surge ...

Renal fibrosis is one of the main pathological features of chronic kidney disease (CKD), and its treatment has been a hot research topic. Recent studies have shown that stem cell therapy can repair ...

Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

Rodman & Renshaw initiated coverage on shares of biopharmaceutical company Talphera (NASDAQ: TLPH) with a Buy rating and a price target of $4.00. The firm's analysts highlighted Talphera's focus on ...

We are delighted that QUELIMMUNE is now available to treat severely ill children at yet another prominent academic medical center,” said Tim Varacek, SeaStar Medical Senior Vice President, Commercial ...

This approach is claimed to improve organ recovery and potentially eliminate future renal replacement therapy (RRT) requirements, including dialysis. The SCD has also gained FDA breakthrough device ...

(You can purchase replacement pods ... then red light therapy won't do much for your hair growth journey. Great news: Spann says red light therapy earned FDA clearance due to its safety.

making it the top-selling drug in the world, STAT explains. Experts say a certain type of bispecific antibody seems to have hit upon a crucial combination of two cancer targets: the proteins VEGF ...